Clinical Trial Update: SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating FLAG-IDA induction therapy for high-risk myelodysplastic syndromes or secondary acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Filgrastim (filgrastim)
• Fludarabine (Fludarabine)
• Idarubicin (idarubicin)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Myelodysplastic Syndrome, Acute Myeloblastic Leukemia | Phase 4 | Status: COMPLETED